The more I look into Qiagen the more concerned I become about the offer. Most of their business is in research and sample preparation. They do have a few diagnostic products but these are mainly molecular biology. Thus I do not see much synergy with a TB business that required physician selling. It is therefore not surprising that Qiagen is putting a low value on the business. I would prefer to see a bid from an established diagnostic company who can add sales and marketing clout to this superb product to ramp up sales. Such a company would see the full worth of the technology and put a higher value on the company. Traditional diagnostic companies such as Roche and Abbott or those with a history in TB (bioMerieux and BD) come to mind. Surely the Directors of the company should now be talking with these companies to secure a better deal rather than trying to convince us shareholders that the existing deal is a good one.
CST Price at posting:
$3.42 Sentiment: None Disclosure: Not Held
